Lumos Pharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LUMO research report →
Companywww.lumos-pharma.com
Lumos Pharma, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders.
- CEO
- Richard J. Hawkins
- IPO
- 2011
- Employees
- 30
- HQ
- Austin, TX, US
Price Chart
Valuation
- Market Cap
- $37.54M
- P/E
- -1.04
- P/S
- 18.30
- P/B
- 1.29
- EV/EBITDA
- -0.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1785.18%
- Net Margin
- -1659.39%
- ROE
- -78.34%
- ROIC
- -107.05%
Growth & Income
- Revenue
- $2.05M · 34.67%
- Net Income
- $-34,034,000 · -9.57%
- EPS
- $-4.18 · -12.67%
- Op Income
- $-36,614,000
- FCF YoY
- -16.71%
Performance & Tape
- 52W High
- $4.58
- 52W Low
- $1.37
- 50D MA
- $4.23
- 200D MA
- $3.10
- Beta
- 0.33
- Avg Volume
- 102.98K
Get TickerSpark's AI analysis on LUMO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 4, 24 | Pitukcheewanont Pisit Duke | other | 0 |
| Jul 1, 24 | Pitukcheewanont Pisit Duke | other | 25,500 |
| Jun 1, 23 | Pitukcheewanont Pisit Duke | other | 29,750 |
| Feb 1, 24 | Pitukcheewanont Pisit Duke | other | 3,333 |
| Aug 1, 23 | McKew John C. | other | 1,593 |
| Aug 2, 23 | McKew John C. | sell | 3,407 |
| Aug 1, 23 | Lawley Lori D | other | 229 |
| May 10, 23 | Zoth Lota S. | other | 3,345 |
| May 10, 23 | van Es-Johansson An | other | 3,345 |
| May 10, 23 | Raffin Thomas A. | other | 3,345 |
Our LUMO Coverage
We haven't published any research on LUMO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LUMO Report →